Absence of galectin-3 does not affect the development of experimental tongue carcinomas in mice
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACADEMIC PRESS INC ELSEVIER SCIENCE
Autores
FARIA, Paulo Rogerio de
MELO, Thaissa Lopes de
HSU, Daniel K.
LIU, Fu-Tong
NONOGAKI, Suely
CARDOSO, Sergio Vitorino
LOYOLA, Adriano Mota
Citação
EXPERIMENTAL AND MOLECULAR PATHOLOGY, v.90, n.2, p.189-193, 2011
Resumo
Background: Galectin-3 is a lectin that presents pivotal roles in tumor biology and there are no studies evaluating their expression in dysplasias and carcinomas developed from tongue carcinogenesis models. Aims: To investigate the role of galectin-3 in the development of tongue carcinomas using a mouse model of oral carcinogenesis. Methods: Galectin-3-deficient (gal3(-/-)) and wild-type (gal3(+/+)) mice were challenged with 4-nitroquinoline-1-oxide in drinking water for 16 weeks and killed at different times. Tongues were removed and the number of dysplasias and carcinomas was counted. An immunohistochemical study for galectin-3 was performed only in the tongue from gal3(+/+) mice. Results: In both groups, a reduction of dysplasias and an increase of carcinomas from week 16 to week 32 (p > 0.05) were observed. A predominance of high cytoplasmic and nuclear galectin-3 expression was observed in carcinomas (64.7%) and dysplasias (55.5%), respectively (p > 0.05). The perilesional areas always presented a statistical cytoplasmic and nuclear galectin-3 overexpression. Conclusions: Absence of galectin-3 did not directly affect the process of carcinogenesis and a cytoplasm shift of galectin-3 seems to be associated with development of tongue carcinomas.
Palavras-chave
Oral carcinogenesis, Galectin-3, Tongue, Mice, Premalignant lesions, Oral squamous cell carcinoma
Referências
- Abdel-Aziz HO, 2008, J CANCER RES CLIN, V134, P777, DOI 10.1007/s00432-007-0345-3
- Plzak J, 2004, EUR J CANCER, V40, P2324, DOI 10.1016/j.ejca.2004.06.025
- Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9
- Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020
- Takenaka Y, 2003, CANCER LETT, V195, P111, DOI 10.1016/S0304-3835(03)00056-9
- LUMERMAN H, 1995, ORAL SURG ORAL MED O, V79, P321, DOI 10.1016/S1079-2104(05)80226-4
- Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3
- Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527
- Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207
- Honjo Y, 2000, CLIN CANCER RES, V6, P4635
- Puglisi F, 2004, CANCER LETT, V212, P233, DOI 10.1016/j.canlet.2004.03.006
- Lee JW, 2006, J CANCER RES CLIN, V132, P241, DOI 10.1007/s00432-005-0069-1
- Vereecken P, 2005, ARCH DERMATOL RES, V296, P353, DOI 10.1007/s00403-004-0536-6
- Betka J, 2003, ACTA OTO-LARYNGOL, V123, P261, DOI 10.1080/0036554021000028128
- Bresalier RS, 1997, CANCER, V80, P776
- Brustmann H, 2006, INT J GYNECOL PATHOL, V25, P30, DOI 10.1097/01.pgp.0000179613.40215.c0
- Castronovo V, 1996, J PATHOL, V179, P43, DOI 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N
- Cvejic D, 2005, EXP ONCOL, V27, P210
- Gillenwater A, 1996, HEAD NECK-J SCI SPEC, V18, P422, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.0.CO;2-7
- Mathieu A, 2005, MODERN PATHOL, V18, P1264, DOI 10.1038/modpathol.3800416
- Piantelli M, 2002, J CLIN ONCOL, V20, P3850, DOI 10.1200/JCO.2002.01.078
- Saussez S, 2008, LARYNGOSCOPE, V118, P1583, DOI 10.1097/MLG.0b013e31817b0718
- Shibata T, 2005, ONCOL REP, V13, P235
- SLOOTWEG PJ, 2005, WORLD HLTH ORG CLASS, P118
- Vairaktaris E, 2008, Oral Oncol, V44, P315, DOI 10.1016/j.oraloncology.2007.08.015
- van den Brule Frederic, 2004, Glycoconjugate Journal, V19, P537
- Weinberger PM, 2007, ARCH OTOLARYNGOL, V133, P503, DOI 10.1001/archotol.133.5.503